ReviewFrontiers in endocrinology2026
The double-edged sword effect of estrogen in kidney disease and its precision modulation.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estrogen, a critical sex hormone, exerts a complex dual role in renal physiology and pathology. While it confers protective effects through anti-inflammatory, anti-fibrotic, and hemodynamic-related signaling pathways-slowing chronic kidney disease (CKD) progression and improving renal function-it may also promote disease under specific pathological contexts. Sexual dimorphism, mediated primarily by estrogen receptor (ER) signaling networks, plays a pivotal role in this duality. This review focuses on the molecular mechanisms of estrogen in kidney disease, the influence of sexual dimorphism, and the double-edged nature of its effects, with an emphasis on precision modulation strategies. By integrating recent basic and clinical findings, we analyze the diverse roles of estrogen across kidney disease models and evaluate its therapeutic potential. Furthermore, we discuss the prospects of applying sex-based precision medicine to kidney disease management, aiming to provide theoretical foundations and guidance for future research and clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.